Department of Cardiology, Pulmonology, and Nephrology,Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan.
✉ Corresponding author: Dr. Yoko Shibata, 2-2-2 Iida-Nishi, Yamagata City, Yamagata 990-9585, Japan. Telephone: +81-23-628-5302 Fax: +81-23-628-5305 Email: shibataid.yamagata-u.ac.jp.
Citation:
Nunomiya K, Shibata Y, Abe S, Inoue S, Igarashi A, Yamauchi K, Kimura T, Aida Y, Nemoto T, Sato M, Kishi H, Nakano H, Sato K, Kubota I. Relationship between Serum Level of Lymphatic Vessel Endothelial Hyaluronan Receptor-1 and Prognosis in Patients with Lung Cancer. J Cancer 2014; 5(3):242-247. doi:10.7150/jca.8486. https://www.jcancer.org/v05p0242.htm
Background: Lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) is a hyaluronic acid receptor that is selectively expressed in the endothelia of lymphatic capillaries. The density of lymphatic vessels expressing LYVE-1 on immunohistochemistry negatively correlates with prognosis of patients with non-small-cell lung cancer. However, the relationship between LYVE-1 serum levels and lung cancer staging is unknown.
Methods: We collected blood samples from 58 lung cancer patients before treatment and measured LYVE-1 serum levels using an enzyme-linked immunosorbent assay.
Results: Mean serum LYVE-1 levels were 1,420 pg/mL. Serum LYVE-1 levels correlated positively with serum albumin levels, but inversely with primary tumor size, leukocyte counts, and platelet counts by Pearson's product-moment correlation coefficient. A high cancer staging, occurrence of lymph-node metastases, and occurrence of distant metastases were significantly associated with low LYVE-1 levels. Moreover, multiple logistic regression analyses revealed that LYVE-1 levels were predictive of the presence of lymph node and distant metastases, independently of the other factors. Kaplan-Meier analysis showed that the survival of patients with serum LYVE-1 ≤1,553 pg/mL was significantly poorer than that of patients with serum LYVE-1 >1,553 pg/mL. This survival difference relative to LYVE-1 levels remained statistically significant after adjusting for age and gender by the Cox proportional-hazard analysis.
Conclusion: Serum LYVE-1 is significantly low in lung cancer patients with metastasis, compared with those without. Measuring LYVE-1 levels in lung cancer patients may be useful for evaluating lung cancer progression.
Nunomiya, K., Shibata, Y., Abe, S., Inoue, S., Igarashi, A., Yamauchi, K., Kimura, T., Aida, Y., Nemoto, T., Sato, M., Kishi, H., Nakano, H., Sato, K., Kubota, I. (2014). Relationship between Serum Level of Lymphatic Vessel Endothelial Hyaluronan Receptor-1 and Prognosis in Patients with Lung Cancer. Journal of Cancer, 5(3), 242-247. https://doi.org/10.7150/jca.8486.
ACS
Nunomiya, K.; Shibata, Y.; Abe, S.; Inoue, S.; Igarashi, A.; Yamauchi, K.; Kimura, T.; Aida, Y.; Nemoto, T.; Sato, M.; Kishi, H.; Nakano, H.; Sato, K.; Kubota, I. Relationship between Serum Level of Lymphatic Vessel Endothelial Hyaluronan Receptor-1 and Prognosis in Patients with Lung Cancer. J. Cancer 2014, 5 (3), 242-247. DOI: 10.7150/jca.8486.
NLM
Nunomiya K, Shibata Y, Abe S, Inoue S, Igarashi A, Yamauchi K, Kimura T, Aida Y, Nemoto T, Sato M, Kishi H, Nakano H, Sato K, Kubota I. Relationship between Serum Level of Lymphatic Vessel Endothelial Hyaluronan Receptor-1 and Prognosis in Patients with Lung Cancer. J Cancer 2014; 5(3):242-247. doi:10.7150/jca.8486. https://www.jcancer.org/v05p0242.htm
CSE
Nunomiya K, Shibata Y, Abe S, Inoue S, Igarashi A, Yamauchi K, Kimura T, Aida Y, Nemoto T, Sato M, Kishi H, Nakano H, Sato K, Kubota I. 2014. Relationship between Serum Level of Lymphatic Vessel Endothelial Hyaluronan Receptor-1 and Prognosis in Patients with Lung Cancer. J Cancer. 5(3):242-247.